---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001704"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:57:05.873599+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eterna receives Nasdaq delisting notice for low MVLS; board changes

## Summary
- Nasdaq notified Eterna on Jan 6, 2025 that MVLS was below $35M for 35 consecutive business days.
- Company has 180-day cure period (until July 7, 2025) to regain compliance with MVLS standard.
- Director Dorothy Clarke resigned Jan 6, 2025; no disagreement with Company; remains general counsel.
- Dr. Elena Ratner appointed to Board effective Jan 7, 2025; determined independent director.

## SEC filing metadata
- accession: 0001493152-25-001704
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001704
- JSON: https://secwatch.observer/filing/0001493152-25-001704.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001704.txt

## Source-grounded claims
- claim_id: 437c6abdacadc48b3af075cf859a40b42eba46d5
  claim: Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  evidence_excerpt: January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm
- claim_id: a1168d2254
  claim: Elena Ratner was appointed as Director at Ernexa Therapeutics Inc..
  evidence_excerpt: On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm
- claim_id: ed827bf71d
  claim: Dorothy Clarke resigned as Director at Ernexa Therapeutics Inc..
  evidence_excerpt: On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000149315225001704/0001493152-25-001704-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.